Israel’s Gamida Cell (reported here previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the hospital.

https://www.timesofisrael.com/hope-grows-for-blood-cancer-patients-as-cell-therapy-firms-key-trial-succeeds/